Petrelintide: Trial Results, Phase 3 Status
Petrelintide: where it is in development, what the trials show so far, and when it could reach patients.
Petrelintide at a glance
Weight loss at 42 weeks as a percent of body weight (ZUPREME-1, compared with 1.7% on placebo).
Its half-life is about 10 days. After 10 d, half is gone, and about 3% remains after five half-lives, for a total of 50 d.
Sources: roche.com, europepmc.org.